Etiology of Parkinson's disease

Canadian Journal of Neurological Sciences

Volumn 30, Issue SUPPL. 1, 2003, Pages

  Huang, Zhigao ^a   De la Fuente Fernández, Raúl ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE;

BRAIN MITOCHONDRION; CIGARETTE SMOKING; DEGENERATIVE DISEASE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC PREDISPOSITION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SUBSTANTIA NIGRA;

EID: 0037351490     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s031716710000319x     Document Type: Review

References (145)

1. Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson's disease. In: Watts RL, Koller WC, (Eds). Movement Disorders. New York: McGraw-Hill, 1997: 137-152.
2. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995; 45(12):2143-2146.
3. Goldman SM, Tanner CM. Etiology of Parkinson's disease. In: Jankovic J, Tolosa E, (Eds). Parkinson's Disease and Movement Disorders. Baltimore, Maryland: Williams and Wilkins, 1998: 133-158.
4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276(5321):2045-2047.
5. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392(6676):605-608.
6. Lai BCL, Marion SA, Teschke K, Tsui JKC. Occupational and environmental risk factors for Parkinson's disease. Parkinsonism and Related Disorders 2002; 8:297-309.
7. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997; 48(3):650-658.
8. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998; 50(5):1346-1350.
9. Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurol Scand 2002; 105(2):77-82.
10. Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet 1983; 2(8365-66):1457-1459.
11. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology 1985; 35(6):841-845.
12. Jendroska K, Olasode BJ, Daniel SE, et al. Incidental Lewy body disease in black Africans. Lancet 1994; 344(8926):882-883.
13. Wang SJ, Fuh JL, Teng EL, et al. A door-to-door survey of Parkinson's disease in a Chinese population in Kinmen. Arch Neurol 1996; 53(1):66-71.
14. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12(4):195-208.
15. Chen RC, Chang SF, Su CL, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001; 57(9):1679-1686.
16. Payami H, Zareparsi S, James D, Nutt J. Familial aggregation of Parkinson's disease: a comparative study of early-onset and late-onset disease. Arch Neurol 2002; 59(5):848-850.
17. de la Fuente-Fernandez R, Calne DB. Familial aggregation of Parkinson's disease. N Engl J Med 2001; 344(15):1168.
18. Calne S, Schoenberg B, Martin W, et al. Familial Parkinson's disease: possible role of environmental factors. Can J Neurol Sci 1987; 14(3):303-305.
19. Sveinbjornsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000; 343(24):1765-1770.
20. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998; 18(3):262-265.
21. Kruger R, Kuhn W, Muller T, et al. A1a30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18(2):106-108.
22. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999; 281(4):341-346.
23. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45(5):577-582.
24. de la Fuente-Fernandez R. Maternal effect on Parkinson's disease. Ann Neurol 2000; 48(5):782-787.
25. de la Fuente-Fernandez R, Calne DB. Evidence for environmental causation of Parkinson's disease. Parkinsonism and Related Disorders 2002; 8:235-241.
26. Dawson VL. Neurobiology. Of flies and mice. Science 2000; 288(5466):631-632.
27. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999; 22:123-144.
28. Spillantini MG, Goedert M. Tau and Parkinson disease. JAMA 2001; 286(18):2324-2326.
29. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388(6645):839-840.
30. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395(6701):451-452.
31. Farrer M, Gwinn-Hardy K, Muenter M, et al. A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet 1999; 8(1):81-85.
32. Valente EM, Bentivoglio AR, Dixon PH, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001; 68(4):895-900.
33. van Duijn CM, Dekker MC, Bonifati V, et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001; 69(3):629-634.
34. Funayama M, Hasegawa K, Kowa H, et al. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51(3):296-301.
35. Scott WK, Nance MA, Watts RL, et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 2001; 286(18):2239-2244.
36. Mouradian MM. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 2002; 58(2):179-185.
37. Shastry BS. Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 2001; 41(1):5-12.
38. Gasser T. Genetics of Parkinson's disease. J Neurol 2001; 248(10):833-840.
39. Vaughan JR, Davis MB, Wood NW. Genetics of parkinsonism: a review. Ann Hum Genet 2001; 65(Pt 2):111-126.
40. Jenner P, Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 1998; 44(3 Suppl 1):S72-S84.
41. Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: the complexity and myriad functions of protein death. Proc Natl Acad Sci USA 1998; 95(6):2727-2730.
42. Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999; 58(1):120- 129.
43. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998; 95(11):6469-6473.
44. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 2001; 21(24):9549-9560.
45. Tofaris GK, Layfield R, Spillantini MG. Alpha-synuclein metabolism and aggregation is linked to ubiquitin- independent degradation by the proteasome. FEBS Lett 2001; 509(1):22-26.
46. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287(5456):1265-1269.
47. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000; 404(6776):394-398.
48. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 2000; 97(2):279-284.
49. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290(5493):985-989.
50. Xu J, Kao S-Y, Lee FJS, et al. Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002; 8(6):600-606.
51. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: clinical and pathologic study in a family. Neurology 1994; 44(3 Pt 1):437-441.
52. Hedrich K, Marder K, Harris J, et al. Evaluation of 50 probands with early-onset Parkinson's disease for parkin mutations. Neurology 2002; 58(8):1239-1246.
53. Zhang Y, Gao J, Chung KK, et al. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A 2000; 97(24):13354-13359.
54. Imai Y, Soda M, Inoue H, et al. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell 2001; 105(7):891-902.
55. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001; 293(5528):263-269.
56. Tanner CM, Chen B, Wang WZ, et al. Environmental factors in the etiology of Parkinson's disease. Can J Neurol Sci 1987; 14(3 Suppl):419-423.
57. Golbe LI, Langston JW. The etiology of Parkinson's disease: new directions for research. In: Jankovic J, Tolosa E, (Eds). Parkinson's Disease and Movement Disorders. Baltimore, Maryland: Williams and Wilkins, 1993: 93-101.
58. Rajput AH, Uitti RJ, Stem W, et al. Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. Can J Neurol Sci 1987; 14(3 Suppl):414-418.
59. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 1999; 14(1):28-37.
60. Anderson C, Checkoway H, Franklin GM, et al. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord 1999; 14(1):21-27.
61. Johnson CC, Gorell JM, Rybicki BA, Sanders K, Peterson EL. Adult nutrient intake as a risk factor for Parkinson's disease. Int J Epidemiol 1999; 28(6):1102-1109.
62. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998; 352(9137):1344-1346.
63. Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000; 21(4):435-440.
64. Ritz B, Yu F. Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 2000; 29(2):323-329.
65. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3(12):1301-1306.
66. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219(4587):979-980.
67. Brownell AL, Jenkins BG, Isacson O. Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease. Biomed Pharmacother 1999; 53(3):131-140.
68. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 1999; 20(2-3):239-247.
69. Semchuk KM, Love EJ, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993; 43(6):1173-1180.
70. Vieregge P, Heinzow B, Korf G, et al. Long-term exposure to manganese in rural well water has no neurological effects. Can J Neurol Sci 1995; 22(4):286-289.
71. Wang WZ, Fang XH, Cheng XM, Jiang DH, Lin ZJ. A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiology 1993; 12(4):209-218.
72. Checkoway H, Powers K, Smith-Weller T, et al. Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am J Epidemiol 2002; 155(8):732-738.
73. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999; 52(1):115-119.
74. Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Environmental risk factors in Parkinson's disease. Mov Disord 1999; 14(6):928-939.
75. Preux PM, Condet A, Anglade C, et al. Parkinson's disease and environmental factors. Matched case-control study in the Limousin region, France. Neuroepidemiology 2000; 19(6):333-337.
76. Mayeux R, Tang MX, Marder K, Cote LJ, Stem Y. Smoking and Parkinson's disease. Mov Disord 1994; 9(2):207-212.
77. Tzourio C, Rocca WA, Breteler MM, et al. Smoking and Parkinson's disease. An age-dependent risk effect? The EUROPARKINSON Study Group. Neurology 1997; 49(5):1267-1272.
78. Tanner CM, Goldman SM, Aston DA, et al. Smoking and Parkinson's disease in twins. Neurology 2002; 58(4):581-588.
79. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson's disease. Am J Epidemiol 1994; 139(12):1129-1138.
80. Quik M, Jeyarasasingam G. Nicotinic receptors and Parkinson's disease. Eur J Pharmacol 2000; 393(1-3):223-230.
81. Baron JA. Cigarette smoking and Parkinson's disease. Neurology 1986; 36(11):1490-1496.
82. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996; 379(6567):733-736.
83. Maggio R, Riva M, Vaglini F, et al. Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 1998; 71(6):2439-2446.
84. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283(20):2674-2679.
85. Chen JF, Xu K, Petzer JP, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21(10):RC143.
86. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001; 18(11):797-806.
87. Tsui JK, Calne DB, Wang Y, Schulzer M, Marion SA. Occupational risk factors in Parkinson's disease. Can J Public Health 1999; 90(5):334-337.
88. Casals J, Elizan TS, Yahr MD. Postencephalitic parkinsonism - a review. J Neural Transm 1998; 105(6-7):645-676.
89. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 1997; 275(5307):1793-1796.
90. Calne DB, Lees AJ. Late progression of post-encephalitic Parkinson's syndrome. Can J Neurol Sci 1988; 15(2):135-138.
91. Lin SK, Lu CS, Vingerhoets FJG, et al. Isolated involvement of substantia nigra in acute transient parkinsonism: MRI and PET observation. Parkinsonism and Related Disorders 1995; 1:67-73.
92. Takahashi M, Yamada T, Nakajima S, et al. The substantia nigra is a major target for neurovirulent influenza A virus. J Exp Med 1995; 181(6):2161-2169.
93. Nielsen NM, Rostgaard K, Hjalgrim H, Aaby P, Askgaard D. Poliomyelitis and Parkinson disease. JAMA 2002; 287(13):1650-1651.
94. Jha N, Jurma O, Lalli G, et al. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease. J Biol Chem 2000; 275(34):26096-26101.
95. Merad-Boudia M, Nicole A, Santiard-Baron D, Saille C, Ceballos-Picot I. Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease. Biochem Pharmacol 1998; 56(5):645-655.
96. Han J, Cheng FC, Yang Z, Dryhurst G. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J Neurochem 1999; 73(4):1683-1695.
97. Soto-Otero R, Mendez-Alvarez E, Hermida-Ameijeiras A, Munoz-Patino AM, Labandeira-Garcia JL. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem 2000; 74(4):1605-1612.
98. Olanow CW, Jenner P, Tatton NA, Tatton WG. Neurodegeneration and Parkinson's disease. In: Jankovic J, Tolosa E, (Eds). Parkinson's Disease and Movement Disorders. Baltimore, Maryland: Williams and Wilkins, 1998: 67-103.
99. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997; 69(3):1196-1203.
100. Sanchez-Ramos J, Overvik E, Overvik ABN. A marker of oxyradical-mediated DNA damage (8-hydroxy-2'deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 1994; 3:197-204.
101. Sian J, Dexter DT, Lees AJ, et al. Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol 1994; 36(3):356-361.
102. Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol 1992; 32(6):799-803.
103. Agid Y, Chase T, Marsden D. Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet 1998; 351(9106):851-852.
104. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43(5):561-575.
105. Rajput AH. The protective role of levodopa in the human substantia nigra. Adv Neurol 2001; 86:327-336.
106. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993; 328(3):176-183.
107. Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992; 32(6):795-798.
108. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 1998; 52:287-300.
109. Youdim MB, Gross A, Finberg JP. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132(2):500-506.
110. Tatton WG, Wadia JS, Ju WY, Chalmers-Redman RM, Tatton NA. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 1996; 48:45-59.
111. Waldmeier PC, Boulton AA, Cools AR, Kato AC, Tatton WG. Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl 2000;60:197-214.
112. Naoi M, Maruyama W, Takahashi T, Akao Y, Nakagawa Y. Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. J Neural Transm Suppl 2000;58:111-121.
113. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet 2000; 355(9201):389-394.
114. Plasterer TN, Smith TF, Mohr SC. Survey of human mitochondrial diseases using new genomic/proteomic tools. Genome Biol 2001; 2(6):RESEARCH0021.
115. Golden TR, Melov S. Mitochondrial DNA mutations, oxidative stress, and aging. Mech Ageing Dev 2001; 122(14):1577-1589.
116. Melov S. Mitochondrial oxidative stress. Physiologic consequences and potential for a role in aging. Ann N Y Acad Sci 2000; 908:219-225.
117. Ebadi M, Muralikrishnan D, Pellett LJ, Murphy T, Drees K. Ubiquinone (coenzyme Q10) and complex I in mitochondrial oxidative disorder of Parkinson's disease. Proc West Pharmacol Soc 2000; 43:55-63.
118. Leret ML, San Millan JA, Fabre E, Gredilla R, Barja G. Deprenyl protects from MPTP-induced Parkinson-like syndrome and glutathione oxidation in rat striatum. Toxicology 2002; 170:165-171.
119. Gu M, Cooper JM, Taanman JW, Schapira AH. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann Neurol 1998; 44(2):177-186.
120. Janetzky B, Hauck S, Youdim MB, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994; 169(1-2):126-128.
121. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1(8649):1269.
122. Cardellach F, Marti MJ, Fernandez-Sola J, et al. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 1993; 43(11):2258-2262.
123. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992; 4(1):27-34.
124. Mizuno Y, Matuda S, Yoshino H, et al. An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann Neurol 1994; 35(2):204-210.
125. Gu M, Gash MT, Cooper JM, et al. Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord 1997; 12(3):418-422.
126. Agid Y. [Aging, disease and nerve cell death]. Bull Acad Natl Med 1995; 179(6):1193-1203.
127. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12(1):25-31.
128. Tatton NA, Maclean-Fraser A, Tatton WG, Perl DP, Olanow CW. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson's disease. Ann Neurol 1998; 44(3 Suppl 1):S142-S148.
129. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998; 13(2):221-227.
130. Jellinger KA. Cell death mechanisms in Parkinson's disease. J Neural Transm 2000; 107(1):1-29.
131. Kosel S, Egensperger R, von Eitzen U, Mehraein P, Graeber MB. On the question of apoptosis in the parkinsonian substantia nigra. Acta Neuropathol (Berl) 1997; 93(2):105-108.
132. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000; 97(6):2875-2880.
133. Jellinger KA, Stadelmann CH. The enigma of cell death in neurodegenerative disorders. J Neural Transm Suppl 2000;60: 21-36.
134. Viswanath V, Wu Y, Boonplueang R, et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 2001; 21(24):9519-9528.
135. Kahns S, Lykkebo S, Jakobsen LD, Nielsen MS, Jensen PH. Caspase-mediated parkin cleavage in apoptotic cell death. J Biol Chem 2002; 277(18):15303-15308.
136. Mogi M, Harada M, Kondo T, et al. bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 1996; 215(2):137-139.
137. Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 1996; 73(4):979-987.
138. Hunot S, Brugg B, Ricard D, et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc Natl Acad Sci USA 1997; 94(14):7531- 7536.
139. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 2000; 23(7):298-304.
140. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996; 46(6):1551-1556.
141. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38(8):1285-1291.
142. Langston JW, Forno LS, Tetrud J, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999; 46(4):598-605.
143. Cicchetti F, Brownell AL, Williams K, et al. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002; 15(6):991-998.
144. Defazio G, Dal Toso R, Benvegnu D, et al. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res 1994; 633(1-2):206-212.
145. Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998; 71(4):1635-1642.